Skip to main content

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Olga Simó Servat

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Desarrollo clínico de GlauSit@, un tratamiento neuroprotector innovador para el glaucoma.

IP: Miguel Angel Zapata Victori
Collaborators: Anna Duarri Piqué, Mercè Abad Martín, Olga Simó Servat, Patricia Bogdanov Baruj, Marta Castany Aregall
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 624300
Reference: CPP2024-011455
Duration: 01/11/2025 - 31/10/2028

Ministerio de Ciencia

Clinical development of RetSit@, a first-in-class neuroprotective drug to treat Early Stages of Diabetic Retinopathy

IP: Olga Simó Servat
Collaborators: Marta Garrido Marin, Miguel Angel Zapata Victori
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 602031
Reference: CPP2023-010602
Duration: 01/10/2024 - 30/09/2027

Ministerio de Ciencia

Clinical development of RetSit@, a first-in-class neuroprotective drug to treat Early Stages of Diabetic Retinopathy

IP: Rafael Simó Canonge
Collaborators: Olga Simó Servat, Marta Garrido Marin, Miguel Angel Zapata Victori
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 602031
Reference: CPP2023-010602
Duration: 01/10/2024 - 30/09/2027

Ministerio de Ciencia

Individualización de la Monitorización continua de glucosa en la población anciana con diabetes mellitus tipo 2 en función del Estado cognitivo

IP: Monica Sanchez Bartres
Collaborators: Marcos Dos Santos Gil, Angel Michael Ortiz Zúñiga, Ana Maria Ortiz de Urbina Olive, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán
Funding agency: Sociedad Española de Diabetes
Funding: 20000
Reference: SED/SANCHEZ/2023
Duration: 01/12/2023 - 31/05/2025

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The document provides recommendations for identifying people who are candidates for these treatments and for guiding their implementation and follow-up in clinical practice.

The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.

Related professionals

Rosa Delia Moran Rodriguez

Rosa Delia Moran Rodriguez

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
Caterina Fernàndez Garberi

Caterina Fernàndez Garberi

Administration and Management
Clinical Neuroimmunology
Read more
Ingrit Vazquez Gonzalez

Ingrit Vazquez Gonzalez

Research technician
Shock, Organ Dysfunction and Resuscitation
Read more
Ares Aurora Villagrasa Vilella

Ares Aurora Villagrasa Vilella

Senior researcher
Liver Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.